Novel SMARTag® Bioconjugation Technology Enables Better-Tolerated ADCs
Summary: SMARTag® technology uses a simple, robust manufacturing process to generate stable, site-specific ADCs. Download this webinar featuring Catalent Biologics Expert, Robyn Barfield, Ph.D., to learn how our RED-106 noncleavable maytansine linker-payload is well-tolerated, offering wider therapeutic windows compared to other technologies, illustrated by our anti-HER2 RED-106 ADC.